- Record: found
- Abstract: found
- Article: not found
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
David Cunningham
1 ,
Ian Chau ,
Deborah D Stocken ,
Juan W Valle ,
David Smith ,
William Steward ,
Peter G Harper ,
Janet Dunn ,
Catrin Tudur-Smith ,
Julia West ,
Stephen Falk ,
Adrian Crellin ,
Fawzi Adab ,
Joyce Thompson ,
Pauline Leonard ,
Joe Ostrowski ,
Martin Eatock ,
Werner Scheithauer ,
Richard Herrmann ,
John P Neoptolemos
Nov 20 2009
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP).
Related collections
Author and article information
Comments
Comment on this article
scite_
0
0
0
0
Smart Citations0
0
0
0
Citing PublicationsSupportingMentioningContrasting
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.